Kiniksa Pharmaceuticals, Ltd. — FY 2022 Form 10-K
Reporting period: Fiscal year ended December 31, 2022. The filing is an annual report, not a standalone fourth-quarter report; financial comparisons below are full-year figures. The audited consolidated financial statements received an unqualified opinion from PwC.
Business context and key financial metrics
Kiniksa is a commercial-stage biopharmaceutical company. Its marketed product is ARCALYST (rilonacept), approved in the U.S. for recurrent pericarditis, CAPS and DIRA. Its principal development programs include KPL-404 and mavrilimumab. The company shares ARCALYST profits with Regeneron.
| Metric | FY 2022 | FY 2021 |
|---|---|---|
| Product revenue, net | $122.5 million | $38.5 million |
| License and collaboration revenue | $97.7 million | None reported |
| Total revenue | $220.2 million | $38.5 million |
| Cost of goods sold | $22.9 million | $9.1 million |
| Collaboration expenses | $24.1 million | $0.8 million |
| Research and development | $65.5 million | $99.3 million |
| Selling, general and administrative | $98.0 million | $85.9 million |
| Operating income (loss) | $9.8 million | $(156.6) million |
| Net income (loss) | $183.4 million | $(157.9) million |
| Operating cash flow | $5.8 million | $(126.3) million |
At year-end, cash and cash equivalents were $122.7 million and short-term investments were $67.9 million, totaling $190.6 million. Current assets were $243.1 million and current liabilities $47.1 million. Total liabilities were $63.5 million; the balance sheet excerpt does not present borrowings or debt. No material debt balance is identified in the supplied filing text.
The company reported a net loss of $492.0 million accumulated through year-end. FY 2022 net income included a $172.3 million income tax benefit, primarily from releasing a valuation allowance on UK deferred tax assets; the filing describes the related deferred tax asset as $185.5 million. Operating cash flow also reflects noncash tax-accounting effects. Accordingly, reported net income is not a direct measure of recurring operating profitability.
For context, product revenue less reported cost of goods sold implies an approximate 81% product gross margin before Regeneron profit sharing and other commercial expenses. Total operating margin was approximately 4%. These are simple calculations from reported figures, not separately stated company metrics.
Material changes versus prior year
- Total revenue increased 471%, with product revenue up 218%, as 2022 was the first full year of ARCALYST sales following its April 2021 launch.
- License and collaboration revenue reached $97.7 million, principally from the Genentech vixarelimab license and the Huadong mavrilimumab license. The filing recognized $87.7 million under the Genentech agreement and $10.0 million under the mavrilimumab agreement.
- R&D expense fell 34%, mainly reflecting lower late-stage trial activity and reduced rilonacept and mavrilimumab costs. KPL-404 R&D increased to $11.6 million from $5.3 million.
- SG&A rose 14%, primarily due to ARCALYST commercial activity. Collaboration expenses increased as ARCALYST sales grew and a $6.0 million payment became due to Regeneron in connection with the Huadong rilonacept agreement.
- The company moved from a large operating loss in 2021 to operating income in 2022, but the much larger reported net income primarily reflects the tax benefit and collaboration revenue, rather than recurring product operations alone.
Outlook, management commentary and risks
- Management expects operating losses for the foreseeable future and says current cash, cash equivalents and short-term investments should fund operating and capital needs for at least 12 months from issuance of the financial statements. It cautions that estimates rely on assumptions and additional financing may be needed.
- Kiniksa expects data from the KPL-404 Phase 2 rheumatoid arthritis trial in the first half of 2024. It reported in January 2023 that enrollment was complete for the second and final multiple-ascending-dose cohort; the proof-of-concept portion was to follow.
- Genentech received exclusive worldwide rights to develop and commercialize vixarelimab. Kiniksa received an $80.0 million upfront payment, became eligible for a further $20.0 million payment after a 2023 supply delivery, and may receive up to approximately $600 million in contingent milestones plus tiered royalties. These contingent amounts are not assured. Kiniksa remains responsible for completing the ongoing Phase 2b prurigo nodularis trial at its own cost.
- Huadong received Asia-Pacific rights, excluding Japan, to ARCALYST and mavrilimumab. Kiniksa received $22.0 million upfront, with further potential milestones and royalties. The $12.0 million rilonacept upfront amount was deferred at year-end pending material deliveries.
- Mavrilimumab’s Phase 3 COVID-19-related ARDS trial did not meet its primary efficacy endpoint; Kiniksa decided not to advance the program in that indication. In February 2022, it also said it did not plan to initiate a Phase 3 GCA trial. The company is exploring collaborative studies in rare cardiovascular diseases.
- Key risks include reliance on ARCALYST’s sustained commercial uptake and payer coverage; expected ongoing losses and possible need for capital; clinical and regulatory uncertainty; and dependence on third-party manufacturing. Regeneron is the sole commercial ARCALYST supplier under the current arrangement, and a potential technology transfer could bring cost, timing and supply risks. The filing also cites competition, intellectual-property limitations, COVID-19 and geopolitical disruption, including the war in Ukraine.
- The company reported no material legal proceedings. Management concluded disclosure controls and internal control over financial reporting were effective as of December 31, 2022.
Most important facts for investors to verify
- Whether ARCALYST prescription growth, net revenue, payer access and patient demand are sustained, and how much of product economics remains after costs and Regeneron’s profit share.
- How much of FY 2022’s net income and operating cash flow is attributable to nonrecurring licensing and tax-accounting effects; in particular, the assumptions supporting realization of UK deferred tax assets.
- Actual cash runway and financing needs as commercial, clinical, manufacturing and potential ARCALYST technology-transfer costs evolve.
- Progress, safety and efficacy results for KPL-404, including timing and outcomes of its proof-of-concept trial; and the scope and cost of completing the vixarelimab trial.
- Whether Huadong and Genentech meet development and commercialization milestones, and whether potential milestone and royalty payments ultimately materialize.
- Continuity and quality of ARCALYST supply, including any technology transfer, and the status of alternative manufacturing capacity.